CRS3123
Clostridioides difficile infection (CDI)
Key Facts
About Crestone
Crestone is a private, clinical-stage biotech company pioneering novel mechanism-of-action antibacterial agents to combat serious and resistant infections. Its most advanced program, CRS3123, has demonstrated promising efficacy and safety in a Phase 2 trial for C. difficile infection, with results published in a top-tier journal. The company's broader pipeline targets significant public health threats like MRSA, VRE, and nontuberculous mycobacterial (NTM) disease, positioning it in the critical fight against antimicrobial resistance (AMR). Founded in 2015 by a team of experienced scientists, Crestone operates as a research-focused organization seeking investment and talent to advance its innovative portfolio.
View full company profileTherapeutic Areas
Other Clostridioides difficile infection (CDI) Drugs
| Drug | Company | Phase |
|---|---|---|
| C. difficile Diagnostics | TechLab | Commercial |
| BioPYM Platform (Lead Program) | Fzata | Pre-clinical |
| Ibezapolstat (ACX-362E) | Acurx Pharmaceuticals | Phase 2b |